The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Biodel's IP Position Strengthened for Ultra-Rapid-Acting Insulin Programs

02-May-2012 | Source : | Visits : 7904
DANBURY, Conn. - Biodel Inc. announced today in a press release that it has received a notice of allowance from the European Patent Office for patent claims covering Biodel's ultra-rapid-acting insulin formulations intended for the treatment of patients with diabetes. The allowed claims cover formulations containing insulin or an insulin analog as an active agent, in which hexameric insulin dissociates to monomeric or dimeric forms. The formulations are in different forms for subcutaneous or sublingual delivery. Method claims cover use of these formulations to treat patients with Type 1 or Type 2 diabetes by subcutaneous or sublingual delivery. Once issued, the claims will have a term that expires in 2025—twenty years from the filing date of the previously issued parent patent.

Biodel's proprietary formulations allow insulin and insulin analogs to disassociate from the six molecule (hexameric) form to low molecular weight forms (dimeric or monomeric forms) and stabilize the low molecular weight forms, minimizing re-association to the hexameric form. It is believed that this promotes more rapid delivery of insulin into the blood when compared to currently marketed rapid-acting insulin analogs and produces desired biological effects. 

Dr. Errol De Souza, Biodel's chief executive officer, stated: "We are gratified by this additional patent coverage, which fortifies the breadth and depth of our multi-pronged ultra-rapid-acting prandial insulin programs. These additional patents are vital to our collaboration and commercialization strategy as we progress our enhanced insulin product candidates through clinical development." 

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.
share



Related Articles